Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million. The biotech—which was launched into the ...
Pills that work similarly to currently available injectable medications represent the next wave of metabolic disorder drugs, and Viking Therapeutics is pushing its drug candidate to the forefront with ...
SAN DIEGO, Nov. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine ...
The MarketWatch News Department was not involved in the creation of this content. Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau ...
Hosted on MSN
Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens
Brian Lian, President and CEO, highlighted several milestones in 2025, focusing on the obesity pipeline: "With the subcutaneous formulation of our lead molecule, VK2735, following the positive ...
The safety and tolerability data were at odds with an earlier phase 1 trial, and not as good as a comparable drug trial result from Eli Lilly. Viking may decide to take VK2735 (oral form) through ...
Viking Therapeutics, Inc.'s Phase 2 oral obesity drug data disappointed, showing high discontinuation rates and no clear efficacy or tolerability edge versus competitors. Viking’s lead candidate, ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company plans to accelerate the oral formulation of VK2735 following Phase 2 results and has also ...
Hosted on MSN
Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial
We recently compiled a list of 11 Best Future Stocks to Buy Now. Viking Therapeutics, Inc. stands third on our list. Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharma company ...
(RTTNews) - Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, reported its fourth-quarter and full-year 2025 financial results ...
Viking Therapeutics is rowing its longboat toward the front of the oral obesity therapy race, posting detailed phase 1 data that suggest its dual agonist of GLP-1 and GIP can hold its own in a crowded ...
VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone beta receptor (TRβ) that possesses selectivity for liver tissue, as well as the beta receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results